🔎 Trials Near Me

Home › Prostate Cancer › Connecticut › New Haven

Prostate Cancer clinical trials in New Haven, CT

21 studies for Prostate Cancer are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

RecruitingPhase 1/2
  • Yale University, New Haven
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06800313

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 2
  • Yale Cancer Center, New Haven
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

RecruitingPhase 3
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06136650

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

RecruitingPhase 1/2
  • GSK Investigational Site, New Haven
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06990880

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

RecruitingPhase 2
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven · 3 mi away
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT05011383

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

RecruitingPhase 3
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0050), New Haven
  • Veterans Affairs Connecticut Healthcare System ( Site 0062), West Haven · 3 mi away
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT06925737

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

RecruitingPhase 1/2
  • Yale Cancer Center, New Haven
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

RecruitingPhase 2
  • Yale Cancer Center, New Haven
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06111781

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

RecruitingPhase 1
  • Yale Cancer Center, New Haven
Ages 18 and older · Men · Updated Sep 8, 2026 · NCT05800665

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth

RecruitingObservational study
  • Wren Laboratories, Branford · 6 mi away
Ages 45 to 80 · Men · Updated Aug 21, 2026 · NCT07454603

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

RecruitingPhase 1
  • Yale New Haven Hospital, New Haven
Ages 18 and older · Men · Updated Aug 21, 2026 · NCT04221542

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

RecruitingPhase 2
  • New Haven Hospital - Yale Cancer Center, New Haven
Ages 18 and older · Men · Updated Aug 17, 2026 · NCT06842498

FOG-001 in Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • Yale University School of Medicine, New Haven
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

RecruitingPhase 1
  • Yale New Haven Hospital, New Haven
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

RecruitingPhase 3
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

RecruitingPhase 1/2
  • Yale University (Data Collection Only), New Haven
Ages 18 and older · Men · Updated Jun 25, 2026 · NCT06457919

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

RecruitingObservational study
  • Yale University, New Haven
Ages 21 and older · Men · Updated May 22, 2026 · NCT03151629

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

RecruitingPhase 1/2
  • Yale University, Yale Cancer Center, New Haven
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

RecruitingPhase 2
  • Smilow Cancer Center/Yale-New Haven Hospital, New Haven
  • Yale University, New Haven
  • Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi away
  • and 2 more
Ages 18 and older · Men · Updated Jan 29, 2026 · NCT05806515

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

RecruitingPhase 3
  • Yale University, New Haven
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
  • Smilow Cancer Hospital Care Center - Guilford, Guilford · 13 mi away
Ages 18 and older · Men · Updated Sep 11, 2025 · NCT03678025

About Prostate Cancer

Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.

More about Prostate Cancer on MedlinePlus

Prostate Cancer trials in other cities

Other studies in New Haven

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.